Peapod Lane Capital LLC Invests $833,000 in Ikena Oncology, Inc. (NASDAQ:IKNA)

Peapod Lane Capital LLC bought a new stake in shares of Ikena Oncology, Inc. (NASDAQ:IKNA - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 507,868 shares of the company's stock, valued at approximately $833,000. Peapod Lane Capital LLC owned 1.05% of Ikena Oncology as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Geode Capital Management LLC raised its stake in Ikena Oncology by 5.6% in the third quarter. Geode Capital Management LLC now owns 271,026 shares of the company's stock valued at $469,000 after purchasing an additional 14,319 shares in the last quarter. FMR LLC lifted its position in shares of Ikena Oncology by 94.1% during the 3rd quarter. FMR LLC now owns 38,374 shares of the company's stock worth $66,000 after buying an additional 18,607 shares during the last quarter. AQR Capital Management LLC acquired a new stake in Ikena Oncology in the second quarter valued at about $36,000. NEA Management Company LLC grew its position in Ikena Oncology by 5.3% in the third quarter. NEA Management Company LLC now owns 600,063 shares of the company's stock valued at $1,038,000 after acquiring an additional 30,013 shares during the last quarter. Finally, BBR Partners LLC raised its stake in Ikena Oncology by 550.0% during the third quarter. BBR Partners LLC now owns 130,000 shares of the company's stock worth $225,000 after acquiring an additional 110,000 shares in the last quarter. 75.00% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Wedbush restated a "neutral" rating and issued a $2.00 price target on shares of Ikena Oncology in a research note on Monday, December 23rd. HC Wainwright restated a "buy" rating and issued a $4.00 target price on shares of Ikena Oncology in a research report on Monday, November 11th.

Ikena Oncology Stock Performance

Shares of Ikena Oncology stock traded down $0.04 on Monday, hitting $1.49. The stock had a trading volume of 213,105 shares, compared to its average volume of 101,402. The stock has a 50 day moving average of $1.55 and a 200 day moving average of $1.65. The firm has a market capitalization of $71.90 million, a P/E ratio of -1.21 and a beta of 0.48. Ikena Oncology, Inc. has a twelve month low of $1.22 and a twelve month high of $1.94.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.